China Approves Galderma's Relfydess for Frown Lines in Adults
China's drug regulator NMPA cleared Galderma's Relfydess for frown lines in adults. The product has already been authorized in more than 35 markets worldwide.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
The National Medical Products Administration of China, known as NMPA, has cleared Relfydess (relabotulinumtoxinA) for temporary treatment of moderate to severe frown lines between the eyebrows in adults, according to a Galderma press release carried by TradingView. The decision widens the company's injectable aesthetics lineup in one of the largest and quickest-growing cosmetic markets.
Galderma says the product comes ready to use as a liquid and needs no reconstitution before injection. The approval relies on a local phase III study in China and the global READY program, which enrolled more than 2,300 participants. Per RTTNews via dpa-AFX, GDERF shares closed Thursday at $220.14, up 10.82%.
why it matters
For investors, this points to geographic growth in the fast-expanding aesthetic medicine segment. The press materials, however, do not quantify how the decision will affect the company's financial results.
market impact
GDERF: wider Asia-Pacific footprint supports the injectables business in one of the region's fastest-growing markets
tags
instruments
sources
- Galderma’s Relfydess™ (relabotulinumtoxinA) Receives Approval in China for Frown Lines — TradingView, 23 October 2026 at 05:00 UTC
- Galderma Expands Relfydess Reach With China Approval For Frown Lines — TradingView, 23 October 2026 at 06:25 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗